<DOC>
	<DOCNO>NCT01079936</DOCNO>
	<brief_summary>The goal clinical research study find high tolerable dose combination Revlimid ( lenalidomide ) high-dose Alkeran ( melphalan ) give patient multiple myeloma receive autologous stem cell transplantation . The safety combination therapy also study .</brief_summary>
	<brief_title>Lenalidomide High-Dose Melphalan</brief_title>
	<detailed_description>The Study Drugs : Melphalan design damage DNA ( genetic material cell ) cell , may cause cancer cell die . High-dose melphalan consider standard care multiple myeloma . Lenalidomide design block protein play role cell function growth , may cause cancer cell die . Study Dose Levels : If agree take part study , assign dose level lenalidomide base join study . Up 4 dose level lenalidomide test safety . The first group participant receive low dose level . Each new group receive high dose group , intolerable side effect see . All participant receive dose level melphalan . Once high tolerable dose combination melphalan lenalidomide find , next group patient randomly assign 1 4 possible group determine computer , base safe effective dose level particular point . Study Drug Administration : You take lenalidomide mouth 1 time day begin 8 day stem cell transplant ( Day -8 ) . You take drug 7 day ( Days -8 -2 ) . You take sips water . On Days -3 -2 , receive melphalan vein 30 minute . On Day 0 , receive chemotherapy study drug , receive infusion stem cell , previously collect . This infusion stem cell give effort help increase blood production strengthen immune system . You receive antibiotic effort decrease likelihood develop infection . Hospitalization follow transplant usually last 2-4 week , may longer . Some participant may discharge early follow outpatient clinic . Study Visits : About 1 month , 3 month , 6 month transplant : - You physical exam medical history record . - Blood ( 2 tablespoon ) urine collect routine test check status disease . - About 3 month transplant , bone marrow biopsy aspiration check status disease . This repeat often , doctor think need . About 1 year transplant : - You physical exam medical history record . - Blood ( 2 tablespoon ) urine collect routine test . - You bone marrow biopsy aspiration check status disease . - You x-rays bone check status disease . Length Study : Your participation study 1 year transplant follow-up visit . If intolerable side effect chemotherapy occur sign disease transplant , take study . If intolerable side effect receive melphalan , still transplant . However , intolerable side effect develop take melphalan , may take study without transplant . If take study early , still may need return routine post-transplant follow-up visit , transplant physician decides necessary . It may life-threatening leave study early conditioning regimen without follow stem cell transplant , blood cell count may dangerously low . This investigational study . Lenalidomide melphalan commercially available FDA approve treatment myeloma . However , use lenalidomide melphalan autologous stem cell transplant investigational . Up 60 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>1 . Patients multiple myeloma relapse progressive disease achieve partial complete response prior conventional therapy autologous stem cell transplantation 2 . Age 18 80 year 3 . Performance score least 80 % Karnofsky performance score 0 1 ( ECOG ) 4 . Left ventricular ejection fraction =/ &gt; 40 % . No uncontrolled arrhythmias symptomatic cardiac disease . 5 . FEV1 , FVC DLCO=/ &gt; 40 % . No symptomatic pulmonary disease . 6 . Serum bilirubin &lt; 2 x upper limit normal , SGPT &lt; 3x upper limit normal . No evidence chronic active hepatitis cirrhosis . No pleural effusion ascites &gt; 1 L prior drainage . 7 . Creatinine Clearance =/ &gt; 50 ml/min 8 . HIV negative 9 . Negative beta HCG test woman child bear potential , define postmenopausal 24 month previous sterilization . 10 . Patients guardian able sign inform consent . 11 . All study participant must register mandatory RevAssist® program , willing able comply requirement RevAssist® . 12 . Females childbearing potential ( FCBP ) must negative serum pregnancy test sensitivity least 50 mIU/mL within 10 14 day prior within 24 hour prescribe lenalidomide ( prescription must fill within 7 day ) must either commit continued abstinence heterosexual intercourse begin TWO acceptable method birth control , one highly effective method one additional effective method AT THE SAME TIME , least 4 week start take lenalidomide . 13 . Contd . FCBP must also agree ongoing pregnancy test . Men must agree use latex condom sexual contact female child bear potential even successful vasectomy . See Appendix F : Risks Fetal Exposure , Pregnancy Testing Guidelines Acceptable Birth Control Methods . 1 . Fertile men woman unwilling use contraceptive technique 12 month follow treatment . 2 . Patients uncontrolled hypertension ( systolic &gt; 140 , diastolic &gt; 90 despite antihypertensive therapy . ) 3 . Patients uncontrolled bacteria , viral fungal infection ( currently take medication progression clinical symptom ) . 4 . Known hypersensitivity desquamate rash either thalidomide lenalidomide . 5 . Women pregnant ( positive ßHCG ) breastfeeding . ( Lactating woman must agree breast feed take lenalidomide 28 day last dose lenalidomide . ) 6 . New York Heart Association ( NYHA ) Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia 's , electrocardiographic evidence acute ischemia , 2nd 3rd degree AV block new leave bundle branch block EKG .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>Revlimid</keyword>
	<keyword>Melphalan</keyword>
	<keyword>Alkeran</keyword>
	<keyword>Autologous stem cell transplantation</keyword>
	<keyword>High-dose chemotherapy</keyword>
</DOC>